Background: The NHL-15 protocol is a novel, dose-intense, dose-dense, sequential chemotherapy program developed to improve outcome in advanced, aggressive non-Hodgkin's lymphomas. Results: There are 165 eligible patients with a 6.9-year median follow-up (range 0.5-141 months) and a median age of 48 years. For the entire group, 72.1% achieved complete remission, and at 5 years disease-free survival was 57.8% and overall survival (OS) was 62.2%. Ideal dose delivery was >90%. Acute and late toxicities of treatment were manageable and acceptable. Toxic death on treatment was 2.4%. When the diffuse large cell lymphoma histologies were grouped according to the International Prognostic Index (IPI), complete remission and OS in the low-intermediate (LI), and high-intermediate (HI) risk groups were improved by 5%-15% compared with historical CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone). This improvement was also noted for LI and HI risk groups in the age-adjusted (aa)IPI analysis for patients < _ 60 years of age. Conclusions: The NHL-15 program can be administered safely and effectively to achieve high rates of durable remission when used for the treatment of advanced stage, aggressive, non-Hodgkin's lymphomas. The 5%-15% improvement in 5-year OS compared with historical CHOP, according to the IPI/aaIPI model (in LI and HI risk groups), is encouraging. Further evaluation and prospective testing of the NHL-15 protocol appears to be warranted.
Introduction
Since the introduction of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) in 1975, many attempts have been made to improve its effectiveness. Although aggressive non-Hodgkin's lymphomas were known to be curable, in 1990 an analysis of chemotherapy regimens utilized in the previous 20 years at Memorial Sloan-Kettering Cancer Center, New York, NY, demonstrated no detectable improvement in treatment outcome during this period [1] . The results of the Intergroup randomized study published in 1993 [2] demonstrated no significant differences in outcome between CHOP, m-BACOD, ProMACE-CytaBOM and MACOP-B, confirming the need to examine new strategies. The NHL-15 phase II protocol was initiated at Memorial Hospital in April 1991 as a novel, high-dose, sequential drug regimen. †A preliminary report of feasibility was presented at the American Society of Hematology, 1992, and published in Hem Onc Annals 1993 [14, 15] .
Based on the tumor growth kinetic models of Norton and Simon [3] , three concepts emerged: (i) dose intensification, in which the dose per unit time is increased; (ii) dose densification, in which chemotherapy is delivered at reduced intervals; and (iii) the utilization of sequential, non-cross-resistant agents/regimens to address tumor cell heterogeneity. Each of these concepts has been tested in aggressive lymphomas and, to date, the results have been mixed. Stumbling blocks to evaluating results have been excess toxicity and the ability to salvage some of those who fail initial therapy. In addition, the recent introduction of rituximab (anti-CD20 antibody) in combination with CHOP (R-CHOP) has led to a significant advance in outcome without major additional toxicity in CD20-positive aggressive lymphomas [4] .
Nevertheless, it is essential that further attempts to improve standard combination chemotherapy continue, as emphasized in a recent editorial by Coiffier [5] . The NHL-15 is a novel, dose-intense, dose-dense, sequential regimen designed to improve outcome, which was studied before the availability of rituximab. The results of this mature clinical trial are reported herein.
Patients and methods

Treatment program
The initial component of treatment (see Granulocyte colony-stimulating factor (G-CSF) was not administered during the induction phase of treatment, either routinely or following dose reduction. G-CSF was only administered during the induction phase as part of the routine management of patients hospitalized for antibiotic treatment of febrile neutropenia. The second phase of treatment, referred to as intensification, consisted of cyclophosphamide 3000 mg/m 2 i.v. on weeks 9, 11 and 13. Mesna was not administered with the cyclophosphamide. On days 3-10 following each cyclophosphamide treatment, G-CSF 5 mg/kg was administered by subcutaneous injection. External beam radiotherapy was not a component of this treatment regimen. Radiotherapy was never used in this series except for post-chemotherapy consolidative scrotal radiotherapy in patients with testicular involvement.
Intrathecal prophylaxis
Intrathecal methotrexate 6 mg/m 2 (maximum 12 mg) was administered on weeks 1, 2, 3, 5, 6 and 7 (or as schedules accommodated) for the following indications: (i) involvement of bone marrow or multiple bony sites; (ii) testicular involvement; or (iii) two or more extranodal sites excluding involvement by extranodal extension.
Dose modifications
Induction. For granulocyte counts >1000 at the time of treatment, doxorubicin was given at full dose. If granulocyte count was >200 but <1000, 65% of the doxorubicin dose was given. For granulocyte counts <200, treatment was held for 1 week. Vincristine dose was not modified for low granulocyte count unless <200, in which case vincristine was also delayed 1 week and administered along with doxorubicin. For grade 3 or 4 constipation, vincristine was held until resolution. The next vincristine dose was reduced by 50% and subsequent doses were escalated by 25% back to baseline as tolerated. Vincristine was discontinued if objective motor weakness was noted or the development of hoarseness of the voice.
Intensification. Cyclophosphamide was held until the granulocyte count was >1000 and platelet count was >50 000, at which point it was given in full dose. Platelet transfusions were administered for platelet counts <20 000/ml.
Patient eligibility
Patients could not have received previous chemotherapy. Enrollment was limited to patients with the following histological diagnoses: diffuse large cell, diffuse large cell immunoblastic type, diffuse mixed small and large cell, follicular large cell, follicular large cell with diffuse areas, and diffuse small cleaved cell lymphomas as defined in the Working Formulation [6] . Patients with Ann Arbor stage II -IV disease, or stage I with a >10 cm tumor mass, were eligible. Primary central nervous system lymphomas were not eligible, and neither were patients presenting with systemic disease who were known to have parenchymal brain or leptomeningeal involvement. All patients were required to have negative serologies for HIV and hepatitis B, and to have serum bilirubin <2 mg/dl and normal baseline cardiac function as defined by multigated equilibrium radionuclide angiography (MUGA) scan or echocardiogram.
Staging evaluation
Diagnostic tissue was obtained for all patients and was reviewed by one of two hematopathologists in the Department of Pathology, Memorial Hospital. A posterior iliac crest bone marrow biopsy and computerized axial tomographic scans of the chest, abdomen and pelvis were obtained for all patients. Lumbar puncture and cytological examination of the cerebrospinal fluid was performed on all patients who met the criteria for intrathecal prophylaxis listed above. Pre-and post-treatment gallium Figure 1 . The NHL-15 treatment regimen.
scanning was not performed routinely on the first 35 patients, but was done for subsequent patients. Additional diagnostic studies were performed as clinically indicated.
Response definitions
All responses were defined prospectively. The following definitions were employed.
Complete remission: no evidence of disease as documented by complete restaging, including biopsy of residual abnormalities, 1 month after completion of last treatment.
Partial response: > _ 50% decrease in the sum of the products of the diameters of each measurable lesion, along with the documented presence of residual disease 1 month following completion of the projected course of treatment.
No response: <50% decrease in the size of measurable lesions, along with the documented presence of residual disease 1 month after completion of treatment.
Progressive disease: the appearance of new lesions or the enlargement of initial sites of disease during treatment.
Relapse: histologically proven recurrence of lymphoma following the achievement of a complete response (CR).
It was not possible to accurately reassess response outcomes retrospectively according to the International Workshop response criteria published in 1999 [7] .
Response evaluation
Interim response evaluations and final determinations of response were conducted between weeks 7 and 9, and between weeks 16 and 17, respectively. Diagnostic studies that defined the initial extent of disease were repeated at these times. Patients demonstrating no response or those with evidence of progression following induction were considered treatment failures and did not go on to intensification. Patients found at the time of final response evaluation to have evidence of residual or progressive lymphoma were considered treatment failures. Residual clinical or radiographic abnormalities remaining at the end of treatment were subjected to surgical or computed tomography (CT)-guided needle biopsy in every case where the risk of the procedure could be justified. Patients whose post-treatment diagnostic evaluation failed to detect evidence of disease were considered to be in remission and received no further treatment. All instances of recurrent disease were confirmed pathologically.
Statistics
Relapse-free survival (RFS) for patients who achieved CR was defined as the time between the end of treatment and the time of relapse or death or time of last follow-up for patients who had not relapsed. Progression-free survival (PFS) was defined as the interval between the start of treatment and the time of treatment failure or relapse, or the time of last follow-up for patients who had neither failed nor relapsed. Overall survival (OS) was defined as the interval between the beginning of treatment and either death or time of last follow-up ( Figure 2 ).
Patients with a diagnosis of diffuse large cell lymphoma (including immunoblastic type) or diffuse mixed small and large cell lymphoma were grouped according to the International Prognostic Index (IPI) and age-adjusted IPI (aaIPI) model using the published criteria [8] (Figure 3 ). RFS, PFS and OS curves were constructed according to the method of Kaplan and Meier [9] . Survival differences between groups were assessed using the log-rank statistic ( Figure 4 ).
Since the sample size was large (n = 2031) and no standard errors could be found in the historical IPI and aaIPI papers [8] , we compared the survival probabilities and CR rates achieved in NHL-15 with the observed rates given in [8] , assuming that the variation in that paper was negligible. The confidence intervals for CR rates were calculated using the exact method.
Drug delivery and dose intensity determinations
The ideal dose intensities for NHL-15 were calculated by dividing the total dose of drug planned by the planned duration of time in weeks over which the drug was to be administered, and was expressed in units of mg/m 2 /week. The actual dose intensity was calculated by dividing the actual amount of drug given by the actual number of weeks elapsed between administration of the first dose and recovery from the last dose. This was done for each patient treated and the data presented are the averages of the dose intensities for individual patients.
Toxicity
Toxicity assessment was made according to National Cancer Institute (NCI) Common Toxicity Criteria.
Informed consent
The Institutional Review Board of Memorial Hospital approved this protocol. All patients enrolled provided written informed consent.
Results
Patient characteristics
Between April 1991 and April 1995, 168 patients were enrolled on the NHL-15 protocol. One hundred and sixty-five patients were evaluable, with a median follow-up of 6.9 years from the date of protocol entry. Three patients were inevaluable due to change in histological diagnosis before treatment. The median age of the 165 evaluable patients was 48 years (range 16 -71 years). The group comprised 99 males and 66 females.
Diffuse large cell lymphoma (including immunoblastic type) and diffuse mixed small and large cell lymphoma represented 73.3% and 10.3% of the evaluable patients, respectively, for a total of 138 (83.6%) patients. This group of patients was analyzed according to the IPI and the aaIPI for those < _ 60 years of age [7] , since these were the histological subtypes for which this model was developed. All IPI analyses were performed retrospectively and data were reviewed independently by three investigators (C.S.P., A.D.Z. and C.H.M.). One patient had inadequate information and was not included in this portion of the analysis. Among the 137 patients in the IPI groups were 14 patients with T-cell lymphomas (three of whom were CD30-positive while 11 were CD30-negative), categorized as either diffuse large cell, or diffuse mixed small and large cell lymphomas. These patients were included in the IPI and aaIPI analyses and were distributed equally among prognostic groups. Follicular large cell lymphoma was present in 12.7% of patients and mantle cell lymphoma was present in 4%. Patient characteristics are shown in Table 1 and compared with the IPI model [8] .
Dose-intensity analysis
The total doses of doxorubicin, vincristine and cyclophosphamide for the NHL-15 program were 240, 7 and 9000 mg/m 2 , respectively. In comparison, for six cycles of CHOP, the total doses were 300, 8.4 and 4500 mg/m 2 for doxorubicin, vincristine and cyclophosphamide respectively. Ninety-one percent of the total planned doxorubicin dose was delivered, as was 96% for vincristine and 97% for cyclophosphamide Table 2 .
Toxicity
The acute toxicities of NHL-15 were collected prospectively in the first 100 patients and are summarized in Table 3 ; acute toxicities of the remaining 65 patients could not be satisfactorily obtained retrospectively and are not reported herein. As expected, myelosuppression was the most common toxicity; however, neutropenia did not significantly limit administration of the regimen. Death during treatment occurred in 2.4% of cases: two patients died of uncontrolled infection (pneumocyctis pneumonia developed in a patient with T-cell lymphoma and one patient with febrile neutropenia ignored fevers at home for 1 week), one patient died of progressive disease, and sudden death occurred in one patient with lymphoma involving the myocardium.
Vincristine-related mild to moderate paraesthesias generally resolved completely over weeks to months following completion of treatment. Neuromotor deficits were uncommon and resolved as expected following discontinuation of vincristine; however, two cases of profound autonomic neuropathy developed after receiving only half the planned vincristine dose. Hoarseness of voice and vocal cord paresis developed in 6% of patients and resolved in every case. Two instances of cardiotoxicity were noted. One patient had a transient 15% reduction in left ventricular ejection fraction (LVEF) following induction and did not proceed to receive high-dose cyclophosphamide. However, LVEF later normalized and this patient remains free of cardiotoxicity. Another patient developed transient apical hypokinesis but went on to complete treatment with subsequent normalization of ventricular function on follow-up examinations. Microscopic hematuria following high-dose cyclophosphamide was noted in 11% of patients. No intervention was necessary, other than encouraging patients to maintain oral hydration. One patient developed hemorrhagic cystitis following the first cycle of high-dose cyclophosphamide. This resolved with conservative management and the final two high-dose cyclophosphamide treatments were administered with mesna and bladder irrigation without incident. Late toxicity assessment was made in 95 patients and these are tabulated in Table 4 . Although a thorough review was made of these records, there may be under-reporting in this retrospective cohort. Late cardiovascular events were present in seven patients (7.4%), with other malignancies in 12 (12.6%). There has been no case of myelodysplasia; one patient developed acute myelogenous leukemia following autologous transplantation.
Response rate
Complete remission was achieved in 119 of 165 patients (72.1%). Of the 46 patients who failed to achieve CR, four patients (2.4%) died while on treatment. One patient was found to have a 15% drop in LVEF following the induction phase of chemotherapy. Because of this he was judged a treatment failure due to toxicity and went on to complete treatment with cyclophosphamide, etoposide, procarbazine and prednisone. Although considered a treatment failure, this patient remains free of disease and is considered evaluable for survival. Complete remission rates, RFS and OS at 5 years for Nausea  42  31  28  50  25  13  5  6  0  0   Vomiting  70  49  16  41  12  25  2 the NHL-15 IPI and aaIPI groups are tabulated and compared with the IPI model in Table 5 . Confidence intervals are provided and tabulated in bold where the confidence interval for NHL-15 does not overlap with the IPI model. Actuarial analyses of relapse-free survival, progression-free survival and overall survival are seen in Figures 2 (all 165 patients) , 3 (for 137 International Prognostic Index classified patients only) and 4 (for 110 patients according to the age-adjusted International Prognostics Index < _ 60 years). Freedom from progression at 5 years is tabulated in Table 6 . Twenty-three patients with relapsed/refractory disease underwent subsequent autologous transplantation, 14 of whom have had prolonged remissions (>1-10+ years). No obvious differences were noted in their ability to tolerate salvage therapy, to obtain adequate stem cell collection and/or to undergo the transplant itself as compared with patients previously treated with CHOP alone. Three patients underwent allotransplants and two remain in remission.
Discussion
The NHL-15 protocol is a novel, dose-intense, dose-dense, sequential drug regimen, tested prospectively in advancedstage aggressive non-Hodgkin's lymphomas. This study reports a 6.9-year median follow-up of a sufficiently large number of patients to address the questions of clinical prognostic factors and survival, as analyzed according to the IPI and aaIPI models [8] .
When initiated in 1991, it was the intention of this study to treat a representative population of patients with advancedstage aggressive non-Hodgkin's lymphomas. For this purpose, advanced stage was considered any disease presentation other than non-bulky stage I, and aggressive lymphomas were considered to be those categorized as either intermediate grade or diffuse large cell immunoblastic (categories D -H) according to the Working Formulation [6] . The median age of patients in this study was 48 years, similar to our previous experience [1] but less than that of the IPI model (median 56 years).
A principal goal of the NHL-15 was to increase significantly the dose intensity of doxorubicin, vincristine and cyclophosphamide, and our data demonstrate clearly that this was achieved (see Table 2 ). The structure of NHL-15 differs from conventional chemotherapy programs by administering drugs sequentially by class (i.e. natural products followed by alkylating agent), thus separating the delivery of doxorubicin and cyclophosphamide, and eliminating the overlap of hematological toxicities that normally limit drug delivery. Moreover, no prednisone was utilized, eliminating some of the potential morbidity seen with CHOP and similar regimens. While facilitating increased dose intensity, the sequential delivery of chemotherapy was not simply a manoeuver to achieve a mathematical end point, but rather an approach emanating from the principles of the Norton-Simon hypothesis [3] . Whether the results of the NHL-15 were adversely affected by the elimination of prednisone and the loss of potential synergy by separating cyclophosphamide and doxorubicin must also be considered. The toxicity of the NHL-15 regimen (Table 3) generally required only routine medical management. Neutropenia did not limit the high percentage of targeted dose intensity that was achieved. However, almost 50% of patients were hospitalized at least once for transient nadir fever, 65% of these admissions during the high-dose cyclophosphamide phase. With rare exceptions, these episodes were brief and uncomplicated. Almost half of all patients received at least one red blood cell transfusion; however, erythropoietin was not utilized. Thrombocytopenia was not seen, except for diseaserelated indications.
With only three drugs in the NHL-15, it was our goal to use each to maximum advantage within the confines of acceptable limits of toxicity. Neurotoxicity was generally more common among older patients, but was not restricted to this group. Whether the level of dose intensification of vincristine attained here is essential remains uncertain. Nonetheless, one must be acutely sensitive to early changes in voice or peripheral motor neuropathy. Discontinuation of vincristine at this point should minimize these troubling toxicities. With careful application of the prescribed dose modifications, however, this regimen can be administered with acceptable toxicity.
With a median follow-up of 6.9 years, late toxicities of the NHL-15 regimen could be assessed. These are listed in Table  4 and appear to be no different than might be expected with CHOP.
Recently, Coiffier [5] summarized all prospective, randomized trials demonstrating a statistically significant benefit of the dose-intense experimental arm as compared with CHOP. He concluded that the weight of these studies suggests that CHOP may be improved by increasing doses and by reducing intervals between cycles. However, Coiffier also cautioned that the R-CHOP regimen [4] appears to provide similar benefit without exposing patients to the more toxic experimental arm. The non-myeloablative experimental data are summarized in Table 7 and provide a benchmark comparison for the NHL-15 protocol. Our mature data appear to compare favorably with the experimental arms of these prospective trials. In the future it will be of interest to determine the additional benefit of rituximab to such dose-intense regimens.
The retrospective comparison of NHL-15 with the IPI/aaIPI model (see Table 5 ) suggests that the NHL-15 regimen may be superior to CHOP in the low-intermediate and highintermediate prognostic categories; however, an assessment of the benefit for patients >60 years of age could not be made due to the small numbers in this group. This apparent NHL-15 improvement may simply be due to the retrospective nature of the comparison, or to better salvage therapy for the NHL-15 patients. A prospective comparison will be needed to confirm these observations. NHL-15 was ineffective in improving outcome for high-risk patients, however. In addition, a retrospective analysis of the NHL-15 patient database looking separately at T-cell, follicular, and mantle cell lymphomas failed to reveal any obvious improvement over historical data with CHOP alone (data not shown).
The NHL-15 protocol is a novel, dose-intense, dose-dense, sequential chemotherapy regimen that can be delivered safely at near ideal dose intensity. The 5%-15% improvement in 5-year OS as compared with historical CHOP, according to the IPI/aaIPI model (in low-intermediate and high-intermediate risk groups), is encouraging. Further evaluation and prospective testing of the NHL-15 appears to be warranted; we are exploring the feasibility of combining Rituximab with the NHL-15 regimen. 
